In:
Pharmacology, S. Karger AG, Vol. 106, No. 11-12 ( 2021), p. 616-622
Abstract:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 A very limited option of inhaled corticosteroids (ICSs) is approved for pediatric use in China because in children the use of ICSs for long periods is associated with dose-dependent growth reduction. Due to the lack of consensus on which is the best ICS-based treatment option to manage mild persistent asthma in children, the present study was performed to evaluate the efficacy and safety of budesonide (BUD)-based therapy vis-à-vis mometasone-based therapy in children with mild persistent asthma. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 A single-center, retrospective study was conducted in asthmatic children aged between 6 and 11 years. BUD and mometasone furoate (MF) were administered as per the approved dosing regimen using pressurized metered-dose inhalers via oral inhalation route for a period of 12 weeks. The study outcome was assessed in terms of the forced expiratory volume in 1 s (FEV 〈 sub 〉 1 〈 /sub 〉 ), symptom scores, and nonoccurrence of side effects. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Among the 77 asthmatic children, 71 completed the study treatment and were used in carrying out the analysis. The improvement of spirometric parameters like FEV 〈 sub 〉 1 〈 /sub 〉 , Tiffeneau-Pinelli index (FEV1/forced vital capacity [FVC]), and peak expiratory flow (PEF) values observed in the MF cohort was significantly greater than those of the BUD cohort ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.05 for all). An increase of approximately 12%/child was observed for FEV 〈 sub 〉 1 〈 /sub 〉 /FVC ratios for the BUD cohort and MF cohorts. After the 12-week study, the PEF 〈 sub 〉 m 〈 /sub 〉 and PEF 〈 sub 〉 e 〈 /sub 〉 values increased to about 50 L/min/child for the BUD cohort and about 98 L/min/child for the MF cohort. During the study, no asthma exacerbation event was observed in the MF cohort, whereas 1 child in the BUD cohort had asthma exacerbation in week 4. The use of rescue medication during the study was required for 16.2 and 6% of children, respectively, for BUD and MF cohorts. Owing to low dosing frequency, MF could provide a better treatment approach than BUD due to improved patient compliance. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 Although both drugs showed improvement in the quality of life of asthmatic children with manageable treatment-emergent adverse effects, the improvement was augmented in MF-treated children. 〈 b 〉 〈 i 〉 Level of Evidence: 〈 /i 〉 〈 /b 〉 The level of evidence was III. 〈 b 〉 〈 i 〉 Technical Efficacy Stage: 〈 /i 〉 〈 /b 〉 The technical efficacy stage was 4.
Type of Medium:
Online Resource
ISSN:
0031-7012
,
1423-0313
Language:
English
Publisher:
S. Karger AG
Publication Date:
2021
detail.hit.zdb_id:
1483550-2
SSG:
15,3
Permalink